Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US National Heart, Lung and Blood Institute (NHLBI) has funded P2D Bioscience for developing anti-inflammatory medicines targeting lung diseases, including asthma, chronic obstructive pulmonary disease (COPD) and acute lung injury/acute respiratory distress syndrome.
Subscribe to our email newsletter
P2D Bioscience has received a sum of $32,000 for establishing the efficacy of these drugs.
The second phase of these studies will investigate the safety and pharmacokinetics of the company’s lead compounds.
Principal investigator on this grant Fillippi said the proposed studies will first assess the validity of the drug target.
"We will determine the efficacy of our lead compounds in biochemical studies by identifying their in vitro efficacy in modulating human neutrophil function," Fillippi said.
"The safe doses of our lead compounds identified in these safety/PK studies will be utilized in efficacy studies employing an in-vivo model of acute lung injury."